

1 **FGF signaling dynamics regulates epithelial patterning and morphogenesis**

2 Jakub Sumbal¹, Tereza Vranova¹, Zuzana Koledova^{1*}

3 ¹Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Brno 625 00,
4 Czech Republic

5 *To whom correspondence should be addressed:

6 Dr. Zuzana Koledova

7 Faculty of Medicine, Masaryk University, Department of Histology and Embryology, Kamenice 3, 625
8 00 Brno, Czech Republic

9 koledova@med.muni.cz

10 ORCID IDs:

11 JS: 0000-0003-3700-4518;

12 ZK: 0000-0002-9333-1399.

13 **Key words:** branching morphogenesis, fibroblast growth factor, mammary gland, organoid, signaling
14 dynamics

15 **Running title:** FGF dynamics regulates epithelial morphogenesis

16 **Summary**

17 Single cell assays revealed that growth factor signaling dynamics is actively sensed by a cell and
18 ultimately controls cell fate. However, the effects of growth factor signaling dynamics at the tissue
19 level have been unknown. We used mammary epithelial organoids, time-lapse imaging, fibroblast
20 growth factor 2 (FGF2) variants of different stabilities, mathematical modeling, and perturbation
21 analysis to study the role of FGF2 signaling dynamics in epithelial morphogenesis. We found that
22 fluctuant and sustained FGF signaling dynamics induced distinct morphological and functional states
23 of mammary epithelium through differential employment of intracellular effectors ERK and AKT. ERK
24 activity domains determined epithelial branch size, while AKT activity drove epithelial stratification.
25 Furthermore, FGF signaling dynamics affected epithelial tissue mechanoresponsiveness to
26 extracellular matrix, thereby impinging upon branch elongation. Our study provides new insights into
27 regulation of epithelial patterning and branching morphogenesis by FGF signaling dynamics and into
28 downstream signaling effectors that regulate cellular outcomes.

29 Introduction

30 Orchestration of complex cell behaviors, such as proliferation, migration, differentiation, and death on
31 population level is essential for building functional tissues during morphogenesis. It is achieved
32 through cell-to-cell communication using core signaling pathways, including receptor tyrosine kinase
33 (RTK) signaling, transforming growth factor signaling, WNT, NOTCH and Hedgehog signaling. Spatial
34 and temporal distribution of various ligands and receptors forms the basic molecular infrastructure for
35 signaling. However, it has long been elusive how activation of a specific receptor translates into a
36 ligand-specific response using just a handful of downstream signaling modules that are common for all
37 receptors within particular signaling pathway family, such as ERK, AKT, STAT and PLC γ in RTK signaling
38 pathways, and how these signaling modules are employed and coordinated in multicellular tissues
39 during formation of complex tissue shapes.

40 Seminal studies in PC12 cell line revealed that on cellular level, different growth factors acting
41 through different RTKs encode different cellular outcomes by inducing distinct temporal patterns of
42 ERK activity - transient or sustained (Gotoh et al., 1990; Nguyen et al., 1993; Santos et al., 2007).
43 Further works elaborated these observations and found that ERK activity dynamics, defined by
44 duration, magnitude, time-course and spatial localization of ERK activity (Muta et al., 2019), acts as a
45 signaling code that defines cell fates (Blum et al., 2019; Ryu et al., 2015). The patterns of ERK activity
46 dynamics are interpreted into cellular outcomes using hierarchical control of gene expression by ERK-
47 regulated transcription factors (Gille et al., 1995; Murphy et al., 2002; Nakakuki et al., 2010). Moreover,
48 the variety of cellular outcomes in response to different growth factors is further increased by
49 differential employment of other downstream signaling pathways, such as AKT, which modulate
50 activity of the effector molecules (Sampattavanich et al., 2018). Current evidence suggests that the
51 sum effect of ligand identity, concentration, temporal dynamics, and combinations with other ligands
52 is sensed, processed and interpreted in a cell-type and context dependent manner (Li and Elowitz,
53 2019). However, it remains poorly understood how these signaling variables are interpreted and how
54 these cellular outcomes are coordinated on a tissue level during morphogenesis.

55 Fibroblast growth factor (FGF) signaling is a crucial pathway that regulates vertebrate
56 development from the earliest embryonic stages throughout lifetime. Regulating cell proliferation,
57 survival, differentiation and migration, it controls a wide range of biological functions (Turner and
58 Grose, 2010). Importantly, FGF signaling has a conserved role in regulation of branching
59 morphogenesis from *Drosophila* to vertebrates, governing development of branched organs such as
60 fly trachea or mammalian lung, kidney, and mammary glands (Lu and Werb, 2008). In mammals,
61 canonical FGF signaling pathway comprises of 15 extracellularly secreted FGFs, which bind to seven
62 isoforms of FGF receptors (FGFRs). Binding of FGF ligand to FGFR results in receptor dimerization,
63 phosphorylation and activation of downstream signalling pathways, including ERK, AKT, PLC γ and
64 STAT3 signaling pathways (Turner and Grose, 2010).

65 Changes in FGF ligand expression, retention, and diffusion, including formation of gradients,
66 and fluctuations in FGF signaling are inherent to mammalian development (Balasubramanian and
67 Zhang, 2016; Makarenkova et al., 2009; Niwa et al., 2007; Ornitz and Itoh, 2015; Wahl et al., 2007).
68 However, it remains incompletely understood how FGF signaling dynamics regulates morphogenesis.
69 Therefore, in this work, we used a well-established experimental model of FGF2-induced branching
70 morphogenesis of primary mammary epithelial organoids (Ewald et al., 2008) to study the role of FGF
71 signaling dynamics in epithelial morphogenesis. To induce various FGF ligand dynamics, we used two
72 variants of FGF2, the wild-type FGF2 (FGF2-wt) and its hyperstable mutant (FGF2-STAB) created by
73 protein engineering (Dvorak et al., 2018). While FGF2-wt is naturally unstable and undergoes fast
74 thermal unfolding and deactivation (half-life approximately 6 h at 37°C), FGF2-STAB exhibits high

75 thermal stability and activity over 30 days at 37°C (Dvorak et al., 2018; Koledova et al., 2019). We
76 applied these ligands in a range of concentrations and medium changing strategies, which created a
77 variety of FGF ligand availability schemes according to mathematical modelling. Using these
78 methodological approaches, we provide new insights into regulation of epithelial patterning and
79 branching morphogenesis by FGF signaling dynamics and the specific roles of downstream signaling
80 components in regulation of distinct morphological outcomes.

81 **Results**

82 **FGF signaling dynamics governs epithelial morphogenesis**

83 To assess the role of FGF signaling dynamics in epithelial morphogenesis, we treated mammary
84 organoids with 1 nM FGF2-wt, which we delivered in a range of different medium changing strategies
85 over 9 days of culture ([Supplemental Figure 1A](#)). The most commonly used strategy in cell culture, with
86 the medium change every three days (C3d), induced formation of thin branches (i.e. normal branching
87 of organoids) as expected ([Figure 1A, B](#)). When the fresh FGF2-wt was added only once at the beginning
88 of culture and was left for the duration of culture with no change (NC) of the medium, or was added
89 only for one- or three-hour pulse (p1h, p3h), no branching was observed, and organoids only mildly
90 grew and formed cysts ([Figure 1A](#)). Increasing frequency of medium change to every day (Ced) or every
91 6 hours (C6h) increased the percentage of branching organoids ([Figure 1A, B](#)) and the phenotype of
92 branching was the same as when the medium was changed every three days. But when we added fresh
93 FGF2-wt every 6 hours (A6h), which is the half-life of FGF2-wt, a new epithelial phenotype emerged,
94 characterized by thick branches, that we named massive branching ([Figure 1A, B](#)). Mathematical
95 modeling of FGF2 concentration in the medium revealed that the condition of adding 1 nM FGF2 every
96 6 hours was the only condition when the concentration of FGF2-wt in the medium did not drop much
97 below 1 nM during the whole organoid culture period ([Figure 1C](#)). This suggested that sustained
98 signaling of 1 nM FGF2 is critical for formation of massive branches.

99 To test this finding, we employed a stabilized form of FGF2 with long-term thermostability,
100 FGF2-STAB (Dvorak et al., 2018). Unlike FGF2-wt, FGF2-STAB remains active after preincubation at 37°C
101 for 7 days and effectively induces branching in the mammary organoids system ([Supplemental Figure](#)
102 [2A, B](#)). We applied the same medium-changing or FGF2-adding strategies with FGF2-STAB as we had
103 done with FGF2-wt. In all these conditions, FGF2-STAB effectively induced epithelial branching, and in
104 most of the conditions FGF2-STAB induced the massive branching phenotype ([Figure 1A-C](#)). Only when
105 the FGF2-STAB was applied in a one- or three-hour pulse, the organoids developed thin branches
106 ([Figure 1A, B](#)). Importantly, these were the only two conditions in which the FGF2 concentration
107 dropped significantly below 1 nM over the organoid culture period ([Figure 1C](#)).

108 **Mathematic modeling reveals a critical dose of FGF signaling for induction of massive branches**

109 To express mathematically the amount of FGF signaling achieved by FGF2 supplied at a known
110 concentration by different medium-changing or FGF2-adding strategies over the organoid culture
111 period, we calculated a „cumulative dose“ for each condition. The cumulative dose corresponds to the
112 area under the curve of the plot modeling FGF2 dynamics over time (see [Methods](#)). These calculations
113 revealed that for FGF2-wt the cumulative dose of FGF signaling increased with increasing frequency of
114 medium change or FGF2 addition. In the case of FGF2-STAB, the cumulative dose of FGF signaling was
115 relatively stable from the no medium change to the medium change every 6 hours strategy ([Figure](#)
116 [1D](#)). Adding FGF2-STAB every 6 hours led to a major increase of the cumulative dose but it had no
117 further effect on the epithelial phenotype, suggesting that the system was already saturated.
118 Importantly, these calculations further showed that only the condition of adding FGF2-wt every 6

119 hours, which was the only one inducing massive branching with FGF2-wt, reached the cumulative dose
120 of FGF signaling similar to the dose achieved by FGF2-STAB at conditions when it induced massive
121 branching (Figure 1D).

122 Furthermore, we exposed the organoids to a wide range of FGF2-wt or FGF2-STAB
123 concentrations under the strategy of medium change every three days. With the increasing
124 concentration of FGF2 the percentage of branching organoids increased for both FGF2-wt and FGF2-
125 STAB, and FGF2-STAB showed a ten times higher total branching inducing potency than FGF2-wt
126 (Figure 1E). FGF2-STAB very effectively induced massive branching of organoids from 1 nM
127 concentration. FGF2-wt induced massive branching only at 20 nM or higher concentrations, yet still
128 only in a low percentage of organoids. The efficiency of induction of massive branching correlated with
129 the cumulative dose of FGF signaling (Figure 1F).

130 Taken together, we found that not only the FGF2 concentration per se, but the temporal
131 dynamics of FGF2 signaling regulates distinct morphogenetic outcomes in the mammary epithelium.
132 When 1 nM FGF2 is supplied, fluctuant FGF signaling induces normal branching, while sustained FGF
133 signaling induces massive branching, as a result of the cumulative dose of FGF acquired over time.

134 **FGF signaling dynamics regulates multiple epithelial cell functions that contribute to the** 135 **morphogenetic outcome**

136 Next, we sought to characterize the new massive branching phenotype, induced by sustained FGF
137 signaling. To this end, we cultured organoids with 1 nM FGF2-wt or FGF2-STAB with medium changed
138 every three days. By careful analysis of time-lapse movies of growing organoids, we found that in
139 massively branching organoids, the branching occurs later than in normally branching organoids and
140 is preceded by an enormous growth of the epithelium (Figure 2A, B; Supplemental Figure 3A,
141 Supplemental Videos 1-3). Histological analysis of the organoids showed that the massive branches
142 induced by sustained FGF signaling were formed by prominently stratified epithelium (Figure 2C;
143 Supplemental Figure 3B). Moreover, the normally and massively branched organoids differed in
144 epithelial cell type distribution. The normal branches of organoids exposed to fluctuant FGF signaling
145 lacked myoepithelial cells at the tips of the branches, a phenomenon previously reported for mammary
146 organoids cultured in Matrigel (Nguyen-Ngoc and Ewald, 2013). However, the massive branches of
147 FGF2-STAB-treated organoids were fully covered by myoepithelial cells (Figure 2C, D; Supplemental
148 Figure 4A, B).

149 Besides altering the shape of organoids, sustained FGF signaling also promoted formation of
150 bigger organoids (Figure 2E). Because in the bright field images the real difference in organoid growth
151 could be masked by lumen enlargement, we also counted the total number of nuclei and the number
152 of BrdU+ nuclei per organoid section to measure organoid proliferation, and we assessed apoptosis
153 using staining for cleaved caspase 3. We found significantly increased number of total nuclei as well as
154 BrdU+ nuclei in FGF2-STAB organoids in comparison to FGF2-wt organoids (Figure 2E, F; Supplemental
155 Figure 5A) and decreased apoptosis in FGF2-STAB organoids (Supplemental Figure 5B, C). The most
156 significant difference in BrdU+ nuclei numbers was found on days 3 and 4, which is when the concentric
157 growth of FGF2-STAB-treated organoids is observed. On day 3 we detected an increased proportion of
158 myoepithelial cells among proliferating cells in FGF2-STAB-treated organoids (Figure 2G; Supplemental
159 Figure 6A), which helps to explain the supply of cells for the full myoepithelial coverage of massively
160 branched organoids (Figure 2C, D).

161 To assess the effect of different FGF signaling dynamics on cell renewal capacity, we
162 dissociated organoids exposed to either no, fluctuant, or sustained FGF signaling to single cells, which
163 we further tested in mammosphere formation assay (Supplemental Figure 7A) or organoid formation

164 assay (Supplemental Figure 7B). Cells derived from FGF2-STAB-treated organoids formed significantly
165 more mammospheres in the third generation (Figure 2H), indicating a higher content of stem cells in
166 FGF2-STAB-treated organoids. In the long-term organoid formation experiment, FGF2-STAB induced
167 formation of bigger and branched organoids, while organoids formed with FGF2-wt were smaller and
168 cystic (Supplemental Figure 7B-D). This suggests that sustained FGF signaling is essential to retain
169 morphogenetic capacity of epithelial cells. Organoids subjected to sustained FGF signaling also showed
170 reduced epithelial polarity, as shown by β -catenin and E-cadherin staining and by ultrastructural
171 analysis of cell-cell connections (Supplemental Figure 8A-C). Additionally, ultrastructural analysis
172 revealed enlarged mitochondria and dilated endoplasmic reticulum in FGF2-STAB treated organoids
173 (Figure 2I; Supplemental Figure 8D), indicating increased metabolic activity of cells subjected to
174 sustained FGF signaling.

175 Together our data show that FGF signaling dynamics regulates a plethora of cell functions,
176 which on tissue level result in different morphogenic outcomes. In comparison to fluctuant FGF
177 signaling, sustained FGF signaling promotes more cell proliferation, including in myoepithelial cells,
178 which contributes to full myoepithelial coverage of massive branches, reduced apoptosis, higher
179 metabolism and increased epithelial cell regenerative and morphogenetic potential. However, while
180 these functions regulate cell number and tissue size, they do not explain how different tissue shapes
181 arise upon different FGF signaling dynamics. We hypothesized a role of downstream signaling
182 pathways, including ERK and AKT, in regulation of tissue architecture.

183 **FGF signaling dynamics regulates epithelial branching via ERK signaling**

184 Organoid branching and branch elongation were demonstrated to be regulated by ERK signaling in
185 response to FGF signaling (Huebner et al., 2016). We hypothesized that ERK signaling regulates branch
186 thickness depending on FGF signaling dynamics. Therefore, we analyzed the effect of ERK signaling
187 inhibition by U0126 on organoid branching morphogenesis upon fluctuant and sustained FGF signaling.
188 U0126 abrogated branching of organoids treated either with FGF2-wt or FGF2-STAB (Figure 3A, B).
189 Interestingly, epithelial stratification and full myoepithelial coverage in response to sustained FGF
190 signaling was not affected by U0126 (Figure 3C; Supplemental Figure 9A). A higher concentration of
191 U0126 was needed to inhibit branching in FGF2-STAB-treated organoids in comparison to FGF2-wt-
192 treated organoids, suggesting higher ERK signaling activity in FGF2-STAB-treated organoids. This was
193 further corroborated by Western blot detection of higher amount of active ERK (phosphorylated ERK,
194 pERK) (Figure 3D) and higher expression of FGF-ERK signaling genes (*Dusp6*, *Etv4* and *Etv5*) by qPCR in
195 FGF2-STAB organoids (Figure 3E).

196 Analysis of spatial distribution of pERK in the organoids revealed that in response to sustained
197 as well as fluctuant FGF signaling, pERK is mosaically distributed early during the morphogenesis in
198 round organoids, but forms distinct domains in the tips of the branches, while the necks of the
199 branches are poor in pERK (Figure 3F). In the branches, pERK positive cells are localized mainly in layers
200 of luminal cells (Figure 3G). Importantly, the domains of pERK were bigger in response to sustained
201 FGF signaling, suggesting that the size of pERK domains determines the thickness of the branches
202 (Figure 3F).

203 **AKT signaling is crucial for epithelial stratification**

204 Besides the ERK pathway, several other signaling pathways act downstream of FGFR, including AKT,
205 STAT and PLC γ pathways. To assess their contribution to the morphogenetic response upon different
206 dynamics of FGF signaling, we used inhibitors of AKT (Akti1/2), STAT3 (Stattic), or PLC γ (U73122). But
207 first as a control that the effects of both FGF2-wt and FGF2-STAB were mediated through FGFR, we
208 used BGJ398, an FGFR inhibitor. BGJ398 effectively inhibited organoid growth and branching

209 morphogenesis in both FGF2-wt- and FGF2-STAB-treated organoids. A higher concentration of BGI398
210 was needed to significantly abrogate branching induced by FGF2-STAB than by FGF2-wt, suggesting a
211 higher level of FGFR signaling induced by FGF2-STAB (Supplemental Figure 10A-C). Inhibition of either
212 STAT3 or PLC γ somewhat decreased normal branching by FGF2-wt and massive branching by FGF2-
213 STAB, but without reaching statistical significance (Supplemental Figure 10A-C). However, inhibition of
214 AKT led to a significant decrease in both FGF2-wt- and FGF2-STAB-induced branching (Figure 4A, B)
215 and, importantly, caused a dramatic loss of massive growth and epithelial stratification induced by
216 sustained FGF signaling (Figure 4A-C). Additionally, we detected elevated amount of phosphorylated
217 AKT (pAKT, activated) in FGF2-STAB-treated organoids (Figure 4D), suggesting that sustained FGF
218 signaling leads to hyperactivation of this pathway.

219 Based on our data from time-lapse imaging (Figure 2A, B) we hypothesized that the concentric
220 massive growth of organoids around day 3 is crucial for subsequent massive branching because the
221 biggest differences in new branch development and proliferation occurs at that time. Therefore, to
222 assess whether at that time the AKT signaling is important for the massive growth, we treated
223 organoids under sustained FGF signaling with Akti1/2 from either day 0, 3, or 6. When Akti1/2 was
224 added on day 6, massive branching occurred, similarly to organoids with no inhibitor (Figure 4E, G).
225 When Akti1/2 was added on day 3, the growth of the organoid was severely reduced, similarly to
226 Akti1/2 addition from day 0 (Figure 4E, F). Importantly, although the growth and stratification of the
227 organoid did not occur, development of new branches was not affected (Figure 4E, G). This suggested
228 that AKT signaling is essential for epithelial stratification.

229 The basal organoid medium, in which the organoids are cultured and exposed to FGF signaling,
230 contains a potent inducer of AKT signaling, insulin. To assess how this additional insulin-induced AKT
231 signaling contributes to organoid morphogenesis, we cultured the organoids under FGF signaling
232 without the insulin-containing component of the basal organoid medium (supplement ITS) or in the
233 presence of insulin receptor inhibitor (BMS 536924). Loss of insulin signaling led to a similar phenotype
234 as the AKT inhibition; total organoid branching was not affected, but the massive growth and epithelial
235 stratification of FGF2-STAB treated organoids were lost completely (Supplemental Figure 11 A-C).

236 At last we inhibited both AKT and ERK signaling at the same time by combination of Akti1/2
237 and U0126. This combined inhibition completely abrogated any morphogenesis (Supplemental Figure
238 12A), similarly to FGFR inhibition (Supplemental Figure 10A-C), suggesting that ERK and AKT pathways
239 are the major pathways orchestrating epithelial morphogenesis downstream of FGF.

240 **Massive branches induced by sustained FGF2 signaling in ex vivo organoids phenocopy terminal end** 241 **buds in vivo**

242 During mammary gland development, soluble signals are integrated with mechanical signals to guide
243 morphogenesis (Gjorevski and Nelson, 2011). Therefore, we investigated the effect of different FGF2
244 signaling dynamics on mammary epithelial morphogenesis in extracellular matrix (ECM) of increased
245 stiffness and fibrillarity – a mixture of Matrigel with collagen I – which is by composition and physical
246 properties closer to ECM in vivo (Nguyen-Ngoc and Ewald, 2013). Concordantly to previous reports
247 (Neumann et al., 2018; Nguyen-Ngoc and Ewald, 2013), we found that in the mixture of Matrigel with
248 collagen, organoids formed significantly longer branches when exposed to fluctuant FGF2 signaling.
249 However, when exposed to sustained FGF2 signaling, the organoid branches did not elongate (Figure
250 5A, B; Supplemental Videos 4 and 5). This suggested uncoupling of FGF2-STAB-treated organoids from
251 mechanical signals of the ECM. To test if the epithelial cells exert mechanical forces on the surrounding
252 ECM, we cultured the organoids in fluorescently labelled collagen. When cells pull on the collagen
253 fibers, the fibers are aligned closer together, increasing fluorescent signal intensity. Aligned collagen

254 was visible around branch necks of the FGF2-wt-treated organoids, but not around the massively
255 branched FGF2-STAB-treated organoids (Figure 5C), demonstrating lack of mechanotransduction
256 between the FGF2-STAB-treated organoid and the surrounding ECM.

257 Furthermore, by histological examination we noticed that by their bulb shape and extensive
258 stratification, the massive branches of FGF2-STAB-treated organoids morphologically resembled
259 terminal end buds (TEBs) of mammary gland in vivo (Figure 5D), the structures that drive mammary
260 epithelial branching morphogenesis during puberty (Paine and Lewis, 2017). FGF2-wt-treated
261 organoids contained branches formed mostly from a bi-layered epithelium and only some tips of the
262 branches contained more than two layers of cells. Thereby, they resembled side branches in the
263 mammary gland in vivo (Figure 5D). Immunohistological analysis of epithelial cell markers further
264 accentuated the similarities between the normal and massive branches ex vivo and side branches and
265 TEBs in vivo, respectively (Figure 5D). Moreover, the myoepithelial cells in massive branches of FGF2-
266 STAB-treated organoids displayed a cuboidal shape similar to cap cells of TEBs, while the myoepithelial
267 cells in the FGF2-wt-treated organoids and in the mammary ducts/side branches in vivo were flatter,
268 based on their height to width ratio on organoid and tissue sections (Figure 5E, F). Collectively, the
269 histology, lack of massive branch elongation in collagenous ECM, and increased regenerative potential
270 of FGF2-STAB-treated organoids (Figure 2H; Supplemental Figure 7A-D) suggest that the massive
271 branches of FGF2-STAB-treated organoids are ex vivo counterparts TEBs in vivo. Thus, our findings
272 propose that distinct signaling dynamics encode different morphogenetic outcomes of physiological
273 relevance (Figure 5G).

274 Discussion

275 In this study, we investigated the role of FGF signaling dynamics in epithelial morphogenesis using the
276 model of mammary epithelial organoids. FGF signaling is a well-established regulator of mammary
277 gland branching morphogenesis (Ewald et al., 2008; Lu et al., 2008; Parsa et al., 2008; Pond et al., 2013;
278 Sumbal and Koledova, 2019; Zhang et al., 2014). In vivo studies using genetic mouse models revealed
279 roles of particular FGFRs in mammary gland morphogenesis (Lu et al., 2008; Parsa et al., 2008). Ex vivo
280 3D cultures of mammary epithelial organoids have elucidated the effects of individual FGF ligands on
281 mammary epithelium (Ewald et al., 2008; Fata et al., 2007; Simian et al., 2001; Zhang et al., 2014).
282 Thus, the role of FGF signaling in mammary epithelial morphogenesis has been well defined on the
283 qualitative level; however, the quantitative aspects of FGF signaling, including the role of FGF signaling
284 dynamics, have not been studied.

285 Using two variants of FGF2 with very different protein stabilities, and different medium
286 changing strategies we exposed organoids to various dynamics of FGF2 availability. We discovered that
287 fluctuant FGF2 signaling induces formation of thin branches, and that sustained FGF2 signaling leads
288 to formation of massive, wide branches. In comparison to fluctuant FGF2 signaling, sustained FGF2
289 signaling led to increased activity of all FGFR downstream signaling pathways. In particular, ERK activity
290 was increased and prolonged in FGF2-STAB-treated organoids in comparison to FGF2-wt-treated
291 organoids. ERK activity dynamics has been suggested to play a key role in regulating mammary
292 epithelial branching morphogenesis in response to different growth factors. In mammary organoid
293 culture, TGF α induced sustained ERK activation and epithelial branching, and FGF7 induced only
294 transient ERK activation and epithelial growth (Fata et al., 2007). Our study corroborates and extends
295 these findings by demonstrating that different ERK activity dynamics, induced downstream of the same
296 receptor, regulate mammary epithelial patterning and morphogenesis. Our study is, however, limited
297 by endpoint-type analytical approaches to ERK activity quantification (immunodetection on fixed
298 samples or Western blot and qPCR analysis at defined timepoints). Future studies using ERK activity

299 biosensors (de la Cova et al., 2017; Komatsu et al., 2011) would be very helpful to elucidate ERK
300 signaling dynamics during mammary epithelial morphogenesis in a much greater detail. Such studies
301 could also help to define the role of ERK signaling domains in epithelial branch patterning and
302 elongation. We found that domains of active ERK were larger in FGF2-STAB-treated organoids than in
303 FGF2-wt-treated organoids and coincided with branch formation sites, suggesting that the size of ERK
304 activity domains determines the diameter of nascent branches. Our experimental data are in
305 agreement with computational simulations of multicellular morphogenesis using reaction-diffusion
306 patterning, in which activator concentration and patterning determine morphological outcome of
307 branching (Okuda et al., 2018). It remains to be determined, how ERK signaling domains become
308 specified within the mammary epithelium.

309 Previous reports suggested that spatial enrichment of active ERK at the tips of the branches
310 drives branch elongation (Huebner et al., 2016). In our model, active ERK was spatially enriched in cells
311 in distal tips of the branches during both normal and massive branching. However, the branches
312 efficiently elongated only in the FGF2-wt-treated organoids. The phenotype was even more prominent
313 in ECM composed of Matrigel with collagen I that was previously demonstrated to promote formation
314 of significantly longer branches than pure Matrigel (Nguyen-Ngoc and Ewald, 2013). This suggests that
315 under sustained FGF2 signaling, epithelial stratification is dominant over epithelial cell intercalation
316 into basal surface, the mechanism required for epithelial tube elongation (Neumann et al., 2018). This
317 is probably due to changes in mechanosignaling in myoepithelial cells and/or changes in their
318 mechanical properties, as suggested by changes in myoepithelial cell geometry and lack of force-
319 mediated collagen I assembly under sustained FGF2 signaling.

320 ERK dynamics alone does not predict the cellular outcome. Rather, cell fate depends on a
321 combination of downstream signaling activities induced by particular growth factor dynamics (Chen et
322 al., 2012; Sampattavanich et al., 2018). On tissue level we detected contribution of AKT-mediated cell
323 activities to epithelial branching, and we identified AKT signaling as a crucial regulator of epithelial
324 stratification and massive branching phenotype. Furthermore, we pinpointed the important role of
325 “basal” AKT signaling, provided by insulin present in the basal medium during ex vivo culture. This is
326 consistent with essential role of insulin-like growth factor 1 in ductal morphogenesis and formation of
327 TEBs (Ruan and Kleinberg, 1999), the naturally occurring stratified mammary epithelial structures that
328 drive mammary branching morphogenesis during puberty. Furthermore, our data demonstrate that
329 inputs from several RTKs are integrated on downstream signaling nodes to regulate tissue
330 morphogenesis in concert.

331 Importantly, our work brings novel insights how intracellular signaling activities of ERK and AKT
332 combinatory regulate distinct morphological and functional states of mammary epithelium. Increased
333 and prolonged ERK and AKT signaling promotes formation of TEB-like structures, while moderate and
334 transient ERK and AKT signaling induces formation of thin branches. In our model these distinct
335 downstream signaling activities and morphogenetic outcomes were induced by different FGF2
336 signaling dynamics and are in concordance with the essential roles of FGF signaling in TEB formation
337 during puberty and in side branching and alveologenesis during pregnancy (Lu et al., 2008; Parsa et al.,
338 2008). The potential mechanisms for regulation of FGF signaling dynamics in vivo include differential
339 production, retention and distribution of FGF ligands in the mammary stroma, differential expression
340 of FGFR isoforms, or differential use of downstream feedback loops (Soady et al., 2017). Furthermore,
341 in vivo the distinct ERK and AKT signaling activities most likely result from combinatorial effects of
342 several growth factors and other signals, such as matrix metalloproteinases, present in the mammary
343 stroma during postnatal mammary gland development, which collectively regulate mammary gland
344 morphogenesis (Gjorevski and Nelson, 2011; Mori et al., 2013).

345 Our study also revealed that the distinct morphological states of mammary epithelium
346 differentially engage ECM to further support epithelial morphogenesis. The non-stratified, side branch-
347 like epithelial structures exert mechanical forces on surrounding collagen, which promotes branch
348 elongation. However, the highly stratified TEB-like epithelial structures do not engage collagen in the
349 surrounding matrix. These findings are in agreement with substantial collagen organization around
350 mammary ducts and necks of TEBs, and lack of organized collagen around TEBs in vivo (Brownfield et
351 al., 2013; Hinck and Silberstein, 2005; Lilla and Werb, 2010).

352 Nevertheless, we acknowledge that by their high proliferation, decreased apoptosis, increased
353 stem cell properties, and multi-layered architecture with intact myoepithelial cell layer, the massively
354 branched epithelial structures induced by sustained FGF2 signaling resemble not only TEBs, but also
355 early, non-invasive stages of breast tumors, including hyperplasia, and their in vitro models induced by
356 oncogenic RTK-Ras signaling (Muthuswamy et al., 2001; Welm et al., 2002). This testifies to the
357 common critical cellular and signaling mechanisms used in both morphogenesis and cancerogenesis.

358 Precise regulation of complex cell behaviors on population level is essential for building
359 functional tissues and organs. It is achieved by cell communication codes that we are only beginning
360 to unravel. Understanding of the signaling codes in development is required for our understanding of
361 aberrant signaling in developmental defects and disease, including cancer, and development of
362 effective therapies. Moreover, it is an essential prerequisite for tissue engineering, stem cell therapy
363 and regenerative medicine. Our study brings insights on how FGF signal availability regulates epithelial
364 branched pattern formation. Future studies using multi-dimensional measurements of intracellular
365 signaling activities on tissue scale with single-cell resolution shall help decipher the cell communication
366 codes, including the relationship between signal processing and cell fate decision-making, during organ
367 development and morphogenesis.

368 **Methods**

369 **Mice**

370 Nulliparous ICR females, 6-8 weeks old were used in this study. The animals were obtained from the
371 Laboratory Animal Breeding and Experimental Facility of the Faculty of Medicine, Masaryk University.
372 Experiments involving animals were approved in accordance with the Ministry of Agriculture of the
373 Czech Republic, and the Expert Committee for Laboratory Animal Welfare at the Faculty of Medicine,
374 Masaryk University.

375 **Organoid isolation and culture**

376 Organoid isolation was performed as previously described (Koledova and Lu, 2017). Briefly, the mice
377 were euthanized by cervical dislocation, the mammary glands were removed, mechanically
378 disintegrated and partially digested in a solution of collagenase and trypsin [2 mg/ml collagenase
379 (Sigma), 2 mg/ml trypsin (Thermo Fisher Scientific), 5 µg/ml insulin (Sigma), 50 µg/ml gentamicin
380 (Sigma), 5% fetal bovine serum (FBS; Hyclone) in DMEM/F12 (Thermo Fisher Scientific)] for 30 min at
381 37°C with shaking at 100 rpm. Resulting tissue suspension was treated with 20 U/ml DNase I (Sigma)
382 and exposed to five rounds of differential centrifugation at 450 × g for 10 s, which resulted in
383 separation of epithelial (organoid) and stromal fractions. The organoids were resuspended in basal
384 organoid medium [BOM; 1× ITS, 100 U/ml of penicillin, and 100 µg/ml of streptomycin in DMEM/F12
385 (all from Thermo Fisher Scientific)] and counted.

386 Subsequently, the organoids were mixed with ECM, either pure Matrigel or a mixture of
387 Matrigel with collagen I. The mixture of Matrigel with collagen I was prepared as previously published
388 (Koledova, 2017). Briefly, pre-assembled neutralized collagen I was prepared by combing 12.5 volumes

389 of collagen type I (Corning) with 1 volume of 0.22 M NaOH, 5× collagen reconstitution buffer (5× MEM,
390 20 µg/ml NaHCO₃, 0.1 M HEPES), and DMEM/F12 to the final concentration 2.58 mg/ml collagen and
391 incubation of the neutralized collagen I for 1.5 h on ice. Then pre-assembled collagen was mixed with
392 Matrigel at the ratio 7:3 and this mixture was immediately used to plate organoids. Fluorescently
393 labelled collagen I was prepared according to a published protocol (Geraldo et al., 2013) using TAMRA
394 (Sigma).

395 The organoids in ECM were plated in 50 µl domes at following densities: 250-300 organoids
396 per dome for time-lapse and whole mount immunofluorescent analysis, 300-500 organoids per dome
397 for histological and transcriptional analysis, 500-1,000 organoids per dome for Western blot analysis.
398 After setting the ECM for 45-60 min at 37°C, the cultures were overlaid with BOM supplied with no
399 FGF, or with FGF2-wt or FGF2-STAB (Enantis) according to the experiment. Unless stated otherwise,
400 concentration of FGF2 was 1 nM. The cultures were incubated in a humidified atmosphere of 5% CO₂
401 at 37°C on Olympus IX81 microscope equipped with Hamamatsu camera and CellR system for time-
402 lapse imaging. The organoids were photographed every 60 min for 9 days with manual refocusing every
403 day. For analysis of cell proliferation, 10 µM BrdU (Sigma) was added to the medium 3 h prior to
404 organoid culture fixation.

405 For long term culture, organoids were cultured for 30 days with media changed every 3 days.
406 Then Matrigel with organoids was disrupted with a 1 ml pipette and treated with trypsin-EDTA for 5
407 min, passed through a 25-gauge needle to obtain single cells. 30,000 cells were seeded in 50 µl Matrigel
408 and treated with BOM with appropriate growth factors. The cells were cultured for 16 days with media
409 changed every 3 days.

410 For inhibitor assays, the organoid cultures were treated with inhibitors in concentrations as
411 indicated ([Supplemental Table 1](#)). Fresh medium with 1 nM FGF2 and/or inhibitors was changed every
412 3 days if not indicated otherwise.

413 **Organoid morphology analysis**

414 Organoid branching was evaluated in ImageJ from time-lapse videos and branching was defined as
415 formation of a new bud/branch from the organoid. Branches wider than 150 µm were considered as
416 “massive branches”. 20 organoids per condition per experiment were analyzed, organoids that fused
417 with another organoid or collapsed after attachment to the bottom of the well were excluded from
418 the quantification.

419 **Organoid histology, immunohistochemistry and immunofluorescence on histological sections**

420 Organoid cultures were washed 3 times with PBS and fixed for 30 min in 4% paraformaldehyde
421 (Electron Microscopy Sciences). After washing with PBS, the cultures were embedded in 3% low gelling
422 temperature agarose (Sigma). After solidification, the samples were dehydrated and embedded in
423 paraffin. Sections (5 µm thick) were cut and dewaxed for hematoxylin and eosin staining or
424 immunostaining.

425 For immunohistochemistry, antigens were retrieved in Citrate buffer, pH 6 or Tris-EDTA buffer,
426 pH 9 (both Dako), endogenous peroxidase activity was blocked using 3% hydrogen peroxide and
427 sections were blocked in PBS with 10% FBS (blocking buffer) for 1 h. Then, sections were incubated
428 with primary antibody in blocking buffer for 2 h. After washing, sections were incubated with
429 secondary antibody in blocking buffer for 30 min. Nuclei were counterstained with Mayer’s
430 hematoxylin, sections were dehydrated and mounted in Pertex (Histolab Products). The samples were
431 photographed using Leica DM5000 equipped with Leica DFC480 camera.

432 To perform immunofluorescence staining, antigens were retrieved in Citrate buffer, pH 6 or
433 Tris-EDTA buffer, pH9 (both Dako), blocked in PBS with 10% FBS (blocking buffer) for 1 h and incubated
434 with primary antibodies in blocking buffer overnight. After washing, sections were incubated with
435 secondary antibodies in blocking buffer for 2 h. Nuclei were counterstained with DAPI for 10 min and
436 slides were mount with Mowiol (Sigma). The samples were photographed using Leica DM5000
437 equipped with Leica DFC480 camera or Zeiss Axioimager 2. Antibodies and their concentrations used
438 in this study are listed in [Supplemental Table 2](#).

439 **Whole-mount organoid staining**

440 For whole-mount imaging, organoids were 3D cultured in coverslip-bottom dishes (Ibidi). Organoid
441 cultures were fixed with 4% paraformaldehyde for 30 min, permeabilized in 0.05% Triton X-100 in PBS
442 for 1 h and blocked for 3 h with blocking buffer. Primary antibodies ([Supplemental Table 2](#)) diluted in
443 blocking buffer were incubated with samples overnight at 4°C. After washing, samples were incubated
444 with secondary antibodies ([Supplemental Table 2](#)) and 2 U/sample phalloidin-AlexaFluor488 (Thermo
445 Fisher Scientific) in blocking solution for 2 h in darkness. Subsequently, samples were stained with 0.5
446 µg/ml DAPI (Merck) for 10 min and stored in PBS in 4°C in darkness until analyzed. The organoids were
447 imaged using an LSM800 confocal microscope (Zeiss) and analyzed and exported using ZEN blue
448 software (Zeiss).

449 **Mammary gland processing for histology**

450 For histological analysis, 4th mammary glands were removed from euthanized mice, spread on
451 microscopy slide and fixed overnight in 4% paraformaldehyde. After washing in tap water, mammary
452 glands were moved to histological cassettes and processed via standard procedure for paraffin
453 embedding. Paraffin sections were cut (5 µm thick), dewaxed using xylene and rehydrated for
454 hematoxylin and eosin staining or immunostaining.

455 **Transmission electron microscopy**

456 The samples were fixed with 3% glutaraldehyde in 100 mM sodium cacodylate buffer, pH 7.4 for 45
457 min, postfixed in 1% OsO₄ for 50 min, and washed with cacodylate buffer. After embedding in 1% agar
458 blocks, the samples were dehydrated in increasing ethanol series (50, 70, 96, and 100%), treated with
459 100% acetone, and embedded in Durcupan resin (Merck). Ultrathin sections were prepared using LKB
460 8802A Ultramicrotome, stained with uranyl acetate and Reynold's lead citrate (Merck), and examined
461 with FEI Morgagni 286(D) transmission electron microscope.

462 **Mammosphere assay**

463 To test primary mammosphere formation efficiency, organoids which had been treated with BOM
464 only, 1 nM FGF2-wt or 1 nM FGF2-STAB, were resuspended on day 4 of culture in 5 mM EDTA in PBS
465 and shaken at 200 rpm on orbital shaker on ice for 1 h to dissolve the Matrigel. After washing with PBS,
466 organoids were treated with HyQtase (Hyclone/GE Healthcare) for 10 min at 37°C and disintegrated
467 by passing through a 24-gauge needle to acquire single cell suspension. Cells were then resuspended
468 in mammosphere medium [1×B27 without vitamin A, 100 U/ml of penicillin, 100 µg/ml of streptomycin
469 (all Thermo Fisher Scientific), 4 µg/ml heparin (Sigma), 20 ng/ml epidermal growth factor (Peprotech),
470 10 ng/ml FGF2-wt (Enantis) in phenol red-free DMEM/F12 (Thermo Fisher Scientific)] and seeded in
471 polyHEMA-coated 6-well plates in concentration 20,000 cells per well. Fresh medium was provided
472 every 3 days. After 9 days of culture, mammospheres were counted and mammosphere formation
473 efficiency was calculated as number of formed mammospheres divided by number of cells seeded ×
474 100. To assess secondary and tertiary mammosphere formation efficiency, primary or secondary

475 mammospheres, respectively, were treated with HyQtase for 10 min at 37°C and disintegrated by
476 passing through a 24-gauge needle to acquire single cell suspension. 20,000 cells per well were seeded
477 in polyHEMA-coated 6-well plates in mammosphere medium and cultured and quantified similarly as
478 primary mammospheres.

479 **Western blot**

480 Organoid cultures were disintegrated by pipetting up and down in ice cold PBS with phosphatase
481 inhibitors (10 mM β -glycerophosphate, 5 mM NaF, 1 mM Na_3VO_4), spun down and lysed in RIPA buffer
482 (150 mM NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) supplied with
483 proteinase and phosphatase inhibitors (10 mM β -glycerophosphate, 5 mM NaF, 1 mM Na_3VO_4 , 1 mM
484 dithiothreitol, 0.5 mM phenylmethanesulphonylfluoride, 2 $\mu\text{g}/\text{ml}$ aprotinin, 10 $\mu\text{g}/\text{ml}$ leupeptin; all
485 Merck). Protein lysates were homogenized by sonication, cleared by centrifugation and protein
486 concentration was measured using the Bradford reagent. Denatured, reduced samples were resolved
487 on 10% SDS-PAGE gels and blotted onto PVDF membranes (Merck). Membranes were blocked with 5%
488 non-fat milk in PBS with 0.05% Tween-20 (Merck; blocking buffer) and incubated with primary
489 antibodies ([Supplemental Table 2](#)) diluted in blocking buffer overnight at 4°C. After washing in PBS
490 with 0.05% Tween-20, membranes were incubated with horseradish peroxidase-conjugated secondary
491 antibodies (anti-mouse antibody and anti-rabbit antibody, Cell Signaling Technology) for 1 h at room
492 temperature. Signal was developed using an ECL substrate (100 mM Tris-HCl, pH 8.5, 0.2 mM coumaric
493 acid, 1.25 mM luminol, 0.01% H_2O_2 ; all Merck) and exposed on X-ray films (Agfa), which were then
494 scanned, and band density was analyzed using ImageJ. Phosphorylated and total proteins and actin
495 were analyzed on a single blot.

496 **qRT-PCR**

497 Organoid cultures were disintegrated by pipetting up and down in RLT buffer (Qiagen) and RNA was
498 isolated using RNeasy Mini Kit (Qiagen) according to the manufacturer's instruction. RNA
499 concentration was measured using NanoDrop 2000 (Thermo Fisher Scientific). RNA was transcribed
500 into cDNA by using Transcriptor First Strand cDNA Synthesis Kit (Roche) or TaqMan Reverse
501 Transcription kit (Life Technologies). Real-time qPCR was performed using 5 ng cDNA, 5 pmol of the
502 forward and reverse gene-specific primers each ([Supplemental Table 3](#)) in Light Cycler SYBR Green I
503 Master mix (Roche) on LightCycler 480 II (Roche). Relative gene expression was calculated using the
504 $\Delta\Delta\text{Ct}$ method and normalization to two housekeeping genes, β -actin (*Actb*) and Eukaryotic elongation
505 factor 1 γ (*Eef1g*).

506 **Mathematical modeling of FGF2 concentration dynamics**

507 Mathematical modeling of FGF2 concentration dynamics was based on half-lives of FGF2 variants: 6 h
508 for FGF2-wt and c.a. 720 h for FGF2-STAB) (Dvorak et al., 2018). Function describing change in
509 concentration (y) dependent on time (x) was determined as shown in (A1).

$$f(t) = c_0 \times \left(\frac{1}{2}\right)^{\frac{t}{t_{1/2}}}$$

510 (A1)

511 In (A1) c_0 is initial concentration of FGF2, t is time in hours and $t_{1/2}$ is half-life of FGF2. For conditions of
512 1 nM FGF with media not changed, function of FGF2 concentration dynamics was determined for FGF2-
513 wt and FGF2-STAB, respectively, as shown in (A2).

$$f_{FGF2-wt}(t) = \left(\frac{1}{2}\right)^{\frac{t}{6}} \quad f_{FGF2-STAB}(t) = \left(\frac{1}{2}\right)^{\frac{t}{720}} \quad (A2)$$

514

515 The area under the curve (AUC) was calculated as a sum of definite integrals with defined intervals as
516 shown in (A3),

$$\sum_1^N \int_0^T c_0 \times \frac{1}{2^{\frac{t}{t_{1/2}}}} \times dt \quad (A3)$$

517

518 Where N is number of media changes (1 for NC; 3 for C3d; 9 for Ced; 36 for C6h); T is a time period
519 determining the duration between two media changes (216 for NC; 72 for C3d; 24 for Ced; 6 for C6h);
520 c_0 is initial concentration; t is time and $t_{1/2}$ is half-life of FGF2.

521 For experiments where medium with FGF2 was washed out, FGF concentration after the washout was
522 determined as zero. For experiment where FGF2 ligands were added every 6 h without changing the
523 medium, the AUC was calculated as a sum of definite integrals of single 6 h intervals with the c_0 =a
524 determined for each interval separately as a function of a sequence given as shown in (A4) and (A5).

$$wt: a_1 = 1; a_{n+1} = 1 + \frac{1}{2}a_n \quad (A4)$$

525

$$STAB: a_1 = 1; a_{n+1} = 1 + \frac{1}{2} \times \frac{6}{720} a_n \quad (A5)$$

526

527 **Statistical analysis**

528 Statistical analysis was performed using Prism software (GraphPad) using unpaired Student's t-test or
529 ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Line plots and bar graphs were generated
530 by Prism or Microsoft Excel and show mean ± standard deviation (s.d.).

531 **Acknowledgement**

532 This research was supported by the Grant Agency of Masaryk University (grant no. MUNI/G/1446/2018
533 to Z.K and by funds from the Faculty of Medicine Masaryk University to junior researcher (Zuzana
534 Koledova, ROZV/28/LF/2020). J.S. was funded by the P-Pool (Masaryk University, Faculty of Medicine)
535 and by the Grant Agency of Masaryk University (grant no. MUNI/A/1565/2018). We thank Katarina
536 Mareckova for excellent histology technical support, Dobromila Klemova for help with preparation of
537 sections for electron microscopy, and Anas Rabata for help with mammosphere assay. We thank
538 Veronika Stepankova, Radka Chaloupkova and Jiri Damborsky for providing the FGF2-wt and FGF2-
539 STAB. We acknowledge the core facility CELLIM of CEITEC supported by the Czech-BioImaging large RI
540 project (LM2018129 funded by MEYS CR) for their support with obtaining scientific data presented in
541 this paper.

542 **Author Contributions**

543 J.S. designed and performed the experiments, analyzed the data and wrote the manuscript. Z.K.
544 conceptualized the study, secured funding, designed and performed the experiments, analyzed the

545 data and wrote the manuscript. T.V. performed immunostainings and analyzed the data. All authors
546 approved the final manuscript.

547 **Conflict of Interest**

548 The authors declare that they have no conflict of interest.

549 **Materials & Correspondence**

550 Correspondence and requests for materials should be addressed to Z.K.

551 **Data availability**

552 Data supporting the findings of this work are available within the paper and its Supplemental
553 Information files. Other data are available from the corresponding author upon reasonable request.


554 **References**

- 555 Balasubramanian, R., and Zhang, X. (2016). Mechanisms of FGF gradient formation during
556 embryogenesis. *Semin. Cell Dev. Biol.* *53*, 94–100.
- 557 Blum, Y., Mikelson, J., Dobrzyński, M., Ryu, H., Jacques, M.-A., Jeon, N.L., Khammash, M., and Pertz,
558 O. (2019). Temporal perturbation of ERK dynamics reveals network architecture of FGF2/MAPK
559 signaling. *Molecular Systems Biology* *15*, e8947.
- 560 Brownfield, D.G., Venugopalan, G., Lo, A., Mori, H., Tanner, K., Fletcher, D.A., and Bissell, M.J. (2013).
561 Patterned collagen fibers orient branching mammary epithelium through distinct signaling modules.
562 *Curr. Biol.* *23*, 703–709.
- 563 Chen, J.-Y., Lin, J.-R., Cimprich, K.A., and Meyer, T. (2012). A two-dimensional ERK-AKT signaling code
564 for an NGF-triggered cell-fate decision. *Mol. Cell* *45*, 196–209.
- 565 de la Cova, C., Townley, R., Regot, S., and Greenwald, I. (2017). A Real-Time Biosensor for ERK Activity
566 Reveals Signaling Dynamics during *C. elegans* Cell Fate Specification. *Dev. Cell* *42*, 542-553.e4.
- 567 Dvorak, P., Bednar, D., Vanacek, P., Balek, L., Eiselleova, L., Stepankova, V., Sebestova, E., Kunova
568 Bosakova, M., Konecna, Z., Mazurenko, S., et al. (2018). Computer-assisted engineering of
569 hyperstable fibroblast growth factor 2. *Biotechnol. Bioeng.* *115*, 850–862.
- 570 Ewald, A.J., Brenot, A., Duong, M., Chan, B.S., and Werb, Z. (2008). Collective epithelial migration and
571 cell rearrangements drive mammary branching morphogenesis. *Dev. Cell* *14*, 570–581.
- 572 Fata, J.E., Mori, H., Ewald, A.J., Zhang, H., Yao, E., Werb, Z., and Bissell, M.J. (2007). The MAPK(ERK-
573 1,2) pathway integrates distinct and antagonistic signals from TGF α and FGF7 in morphogenesis
574 of mouse mammary epithelium. *Dev. Biol.* *306*, 193–207.
- 575 Geraldo, S., Simon, A., and Vignjevic, D.M. (2013). Revealing the cytoskeletal organization of invasive
576 cancer cells in 3D. *J Vis Exp* e50763.
- 577 Gille, H., Kortenjann, M., Thomae, O., Moomaw, C., Slaughter, C., Cobb, M.H., and Shaw, P.E. (1995).
578 ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation.
579 *EMBO J.* *14*, 951–962.

- 580 Gjorevski, N., and Nelson, C.M. (2011). Integrated morphodynamic signalling of the mammary gland.
581 *Nat. Rev. Mol. Cell Biol.* *12*, 581–593.
- 582 Gotoh, Y., Nishida, E., Yamashita, T., Hoshi, M., Kawakami, M., and Sakai, H. (1990). Microtubule-
583 associated-protein (MAP) kinase activated by nerve growth factor and epidermal growth factor in
584 PC12 cells. Identity with the mitogen-activated MAP kinase of fibroblastic cells. *Eur. J. Biochem.* *193*,
585 661–669.
- 586 Hinck, L., and Silberstein, G.B. (2005). Key stages in mammary gland development: The mammary
587 end bud as a motile organ. *Breast Cancer Research* *7*, 245.
- 588 Huebner, R.J., Neumann, N.M., and Ewald, A.J. (2016). Mammary epithelial tubes elongate through
589 MAPK-dependent coordination of cell migration. *Development* *143*, 983–993.
- 590 Koledova, Z. (2017). 3D Coculture of Mammary Organoids with Fibrospheres: A Model for Studying
591 Epithelial-Stromal Interactions During Mammary Branching Morphogenesis. *Methods Mol. Biol.*
592 *1612*, 107–124.
- 593 Koledova, Z., and Lu, P. (2017). A 3D Fibroblast-Epithelium Co-culture Model for Understanding
594 Microenvironmental Role in Branching Morphogenesis of the Mammary Gland. *Methods Mol. Biol.*
595 *1501*, 217–231.
- 596 Koledova, Z., Sumbal, J., Rabata, A., de La Bourdonnaye, G., Chaloupkova, R., Hrdlickova, B.,
597 Damborsky, J., and Stepankova, V. (2019). Fibroblast Growth Factor 2 Protein Stability Provides
598 Decreased Dependence on Heparin for Induction of FGFR Signaling and Alters ERK Signaling
599 Dynamics. *Front Cell Dev Biol* *7*, 331.
- 600 Komatsu, N., Aoki, K., Yamada, M., Yukinaga, H., Fujita, Y., Kamioka, Y., and Matsuda, M. (2011).
601 Development of an optimized backbone of FRET biosensors for kinases and GTPases. *Mol Biol Cell* *22*,
602 4647–4656.
- 603 Li, P., and Elowitz, M.B. (2019). Communication codes in developmental signaling pathways.
604 *Development* *146*.
- 605 Lilla, J.N., and Werb, Z. (2010). Mast cells contribute to the stromal microenvironment in mammary
606 gland branching morphogenesis. *Developmental Biology* *337*, 124–133.
- 607 Lu, P., and Werb, Z. (2008). Patterning mechanisms of branched organs. *Science* *322*, 1506–1509.
- 608 Lu, P., Ewald, A.J., Martin, G.R., and Werb, Z. (2008). Genetic mosaic analysis reveals FGF receptor 2
609 function in terminal end buds during mammary gland branching morphogenesis. *Dev Biol* *321*, 77–
610 87.
- 611 Makarenkova, H.P., Hoffman, M.P., Beenken, A., Eliseenkova, A.V., Meech, R., Tsau, C., Patel, V.N.,
612 Lang, R.A., and Mohammadi, M. (2009). Differential interactions of FGFs with heparan sulfate control
613 gradient formation and branching morphogenesis. *Sci Signal* *2*, ra55.
- 614 Mori, H., Lo, A.T., Inman, J.L., Alcaraz, J., Ghajar, C.M., Mott, J.D., Nelson, C.M., Chen, C.S., Zhang, H.,
615 Bascom, J.L., et al. (2013). Transmembrane/cytoplasmic, rather than catalytic, domains of Mmp14
616 signal to MAPK activation and mammary branching morphogenesis via binding to integrin β 1.
617 *Development* *140*, 343–352.

- 618 Murphy, L.O., Smith, S., Chen, R.-H., Fingar, D.C., and Blenis, J. (2002). Molecular interpretation of
619 ERK signal duration by immediate early gene products. *Nat. Cell Biol.* *4*, 556–564.
- 620 Muta, Y., Matsuda, M., and Imajo, M. (2019). Divergent Dynamics and Functions of ERK MAP Kinase
621 Signaling in Development, Homeostasis and Cancer: Lessons from Fluorescent Bioimaging. *Cancers*
622 (Basel) *11*.
- 623 Muthuswamy, S.K., Li, D., Lelievre, S., Bissell, M.J., and Brugge, J.S. (2001). ErbB2, but not ErbB1,
624 reinitiates proliferation and induces luminal repopulation in epithelial acini. *Nat. Cell Biol.* *3*, 785–
625 792.
- 626 Nakakuki, T., Birtwistle, M.R., Saeki, Y., Yumoto, N., Ide, K., Nagashima, T., Bruschi, L., Ogunnaike,
627 B.A., Okada-Hatakeyama, M., and Kholodenko, B.N. (2010). Ligand-specific c-Fos expression emerges
628 from the spatiotemporal control of ErbB network dynamics. *Cell* *141*, 884–896.
- 629 Neumann, N.M., Perrone, M.C., Veldhuis, J.H., Huebner, R.J., Zhan, H., Devreotes, P.N., Brodland,
630 G.W., and Ewald, A.J. (2018). Coordination of Receptor Tyrosine Kinase Signaling and Interfacial
631 Tension Dynamics Drives Radial Intercalation and Tube Elongation. *Dev. Cell* *45*, 67-82.e6.
- 632 Nguyen, T.T., Scimeca, J.C., Filloux, C., Peraldi, P., Carpentier, J.L., and Van Obberghen, E. (1993). Co-
633 regulation of the mitogen-activated protein kinase, extracellular signal-regulated kinase 1, and the
634 90-kDa ribosomal S6 kinase in PC12 cells. Distinct effects of the neurotrophic factor, nerve growth
635 factor, and the mitogenic factor, epidermal growth factor. *J. Biol. Chem.* *268*, 9803–9810.
- 636 Nguyen-Ngoc, K.-V., and Ewald, A.J. (2013). Mammary ductal elongation and myoepithelial migration
637 are regulated by the composition of the extracellular matrix. *J Microsc* *251*, 212–223.
- 638 Niwa, Y., Masamizu, Y., Liu, T., Nakayama, R., Deng, C.-X., and Kageyama, R. (2007). The initiation and
639 propagation of Hes7 oscillation are cooperatively regulated by Fgf and notch signaling in the somite
640 segmentation clock. *Dev. Cell* *13*, 298–304.
- 641 Okuda, S., Miura, T., Inoue, Y., Adachi, T., and Eiraku, M. (2018). Combining Turing and 3D vertex
642 models reproduces autonomous multicellular morphogenesis with undulation, tubulation, and
643 branching. *Sci Rep* *8*, 2386.
- 644 Ornitz, D.M., and Itoh, N. (2015). The Fibroblast Growth Factor signaling pathway. *Wiley Interdiscip*
645 *Rev Dev Biol* *4*, 215–266.
- 646 Paine, I.S., and Lewis, M.T. (2017). The Terminal End Bud: the Little Engine that Could. *J Mammary*
647 *Gland Biol Neoplasia* *22*, 93–108.
- 648 Parsa, S., Ramasamy, S.K., De Langhe, S., Gupte, V.V., Haigh, J.J., Medina, D., and Bellusci, S. (2008).
649 Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling. *Dev. Biol.*
650 *317*, 121–131.
- 651 Pond, A.C., Bin, X., Batts, T., Roarty, K., Hilsenbeck, S., and Rosen, J.M. (2013). Fibroblast growth
652 factor receptor signaling is essential for normal mammary gland development and stem cell function.
653 *Stem Cells* *31*, 178–189.
- 654 Ruan, W., and Kleinberg, D.L. (1999). Insulin-like growth factor I is essential for terminal end bud
655 formation and ductal morphogenesis during mammary development. *Endocrinology* *140*, 5075–5081.

- 656 Ryu, H., Chung, M., Dobrzyński, M., Fey, D., Blum, Y., Lee, S.S., Peter, M., Kholodenko, B.N., Jeon,
657 N.L., and Pertz, O. (2015). Frequency modulation of ERK activation dynamics rewires cell fate. *Mol.*
658 *Syst. Biol.* *11*, 838.
- 659 Sampattavanich, S., Steiert, B., Kramer, B.A., Gyori, B.M., Albeck, J.G., and Sorger, P.K. (2018).
660 Encoding Growth Factor Identity in the Temporal Dynamics of FOXO3 under the Combinatorial
661 Control of ERK and AKT Kinases. *Cell Syst* *6*, 664-678.e9.
- 662 Santos, S.D.M., Verveer, P.J., and Bastiaens, P.I.H. (2007). Growth factor-induced MAPK network
663 topology shapes Erk response determining PC-12 cell fate. *Nat. Cell Biol.* *9*, 324–330.
- 664 Simian, M., Hirai, Y., Navre, M., Werb, Z., Lochter, A., and Bissell, M.J. (2001). The interplay of matrix
665 metalloproteinases, morphogens and growth factors is necessary for branching of mammary
666 epithelial cells. *Development* *128*, 3117–3131.
- 667 Soady, K.J., Tornillo, G., Kendrick, H., Meniel, V., Olijnyk-Dallis, D., Morris, J.S., Stein, T., Gusterson,
668 B.A., Isacke, C.M., and Smalley, M.J. (2017). The receptor protein tyrosine phosphatase PTPRB
669 negatively regulates FGF2-dependent branching morphogenesis. *Development* *144*, 3777–3788.
- 670 Sumbal, J., and Koledova, Z. (2019). FGF signaling in mammary gland fibroblasts regulates multiple
671 fibroblast functions and mammary epithelial morphogenesis. *Development* *146*.
- 672 Turner, N., and Grose, R. (2010). Fibroblast growth factor signalling: from development to cancer.
673 *Nat. Rev. Cancer* *10*, 116–129.
- 674 Wahl, M.B., Deng, C., Lewandoski, M., and Pourquié, O. (2007). FGF signaling acts upstream of the
675 NOTCH and WNT signaling pathways to control segmentation clock oscillations in mouse
676 somitogenesis. *Development* *134*, 4033–4041.
- 677 Welm, B.E., Freeman, K.W., Chen, M., Contreras, A., Spencer, D.M., and Rosen, J.M. (2002). Inducible
678 dimerization of FGFR1 development of a mouse model to analyze progressive transformation of the
679 mammary gland. *J Cell Biol* *157*, 703–714.
- 680 Zhang, X., Martinez, D., Koledova, Z., Qiao, G., Streuli, C.H., and Lu, P. (2014). FGF ligands of the
681 postnatal mammary stroma regulate distinct aspects of epithelial morphogenesis. *Development* *141*,
682 3352–3362.
- 683




684

685 **Figure 1. FGF signaling dynamics governs epithelial morphogenesis.**

686 **A.** Organoids after 9 days of culture with different FGF signaling dynamics as depicted in **C**. Scale bars,
 687 200 μ m. P1h, 1-hour pulse; p3h, 3-hour pulse; NC, medium was not changed during the whole 9-day
 688 culture of organoids; C3d, medium was changed every 3 days; Ced, medium was changed every day;
 689 C6h, medium was changed every 6 h; A6h, fresh FGF2 was added to the medium every 6 h and every
 690 3 days, the full medium volume was changed.

- 691 **B.** Total (normal + massive) branching and massive branching of organoids subjected to different
692 medium changing strategies. The plots show mean + s.d., N = 20-100 organoids, n = 1-5 independent
693 experiments; for exact numbers see [Supplemental Table 4](#). The asterisks indicate significant difference
694 between FGF2-wt and FGF2-STAB per condition; *P < 0.05; ****P < 0.0001 (two-way ANOVA).
- 695 **C.** The graphs show mathematic models of FGF2 concentration dynamics in culture during different
696 medium changing strategies. The models are based on the FGF2 half-lives (6 h for FGF2-wt and 720 h
697 for FGF2-STAB). Potential active FGF2 degradation or production by the cells was not accounted for.
698 FGF2-wt is depicted in grey, FGF2-STAB in pink. Insets show detail of FGF dynamic during the first day
699 of culture.
- 700 **D.** The plot shows cumulative FGF2 dose, calculated from the mathematic model of FGF2
701 concentration dynamics as the area under the curves shown in **C**.
- 702 **E.** Analysis of organoid morphogenetic response to a range of FGF2 concentrations. The plots show
703 quantification of total (normal + massive) branching and massive branching of organoids, respectively,
704 in response to a range of FGF2 concentrations. The plots show mean + s.d., N = 20-180 organoids, n =
705 1-9 independent experiments; for exact numbers see [Supplemental Table 4](#). The asterisks indicate
706 significant difference between FGF2-wt and FGF2-STAB per condition; **P < 0.01; ****P < 0.0001 (two-
707 way ANOVA).
- 708 **F.** The plot shows cumulative FGF2 dose, calculated from the mathematic model of FGF2 concentration
709 dynamics as the area under the curve.



710

711 **Figure 2. Sustained FGF signaling regulates multiple epithelial cell functions.**

712 **A.** Morphogenesis of organoids with no FGF, 1 nM FGF2-wt, or 1 nM FGF2-STAB. Snapshots are from
713 a time-lapse experiment (see also [Supplemental Videos 1-3](#)). Scale bars, 200 μm.

714 **B.** Temporal analysis of organoid morphogenetic phenotypes. Light gray, no branching; dark gray
715 normal branching; dark red, massive branching. A sum of three independent experiments with 20
716 organoids tracked per condition per experiment.

717 **C.** Whole-mount, histology and immunofluorescence of FGF2-wt- or FGF2-STAB-treated organoids.
718 α SMA, α smooth muscle actin; H and E, hematoxylin and eosin; KRT5, keratin 5; KRT8, keratin 8. Scale
719 bars, 100 μ m.

720 **D.** Quantification of branch coverage with α SMA+ cells.


721 **E.** Quantification of organoid growth from time-lapse experiments and from total number of nuclei or
722 BrdU+ nuclei (shown in **B** and [Supplemental Figure 5A](#)). The plot shows mean + s.d., n = 3, N = 60
723 organoids (time-lapse) and N = 3-40 organoids (histology) per condition; for exact numbers see
724 [Supplemental Table 5](#). Red asterisks indicate the difference between FGF2-STAB and no FGF, blue
725 asterisks between FGF2-wt and no FGF, black asterisks between FGF2-wt and FGF2-STAB. *P < 0.05;
726 **P < 0.01; ***P < 0.001; ****P < 0.0001 (two-way ANOVA for time-lapse experiment; multiple t-tests
727 with Holm-Sidak's test for histology).

728 **F.** BrdU staining of organoids treated with FGF2-wt or FGF2-STAB for 3 or 7 days. Scale bars, 50 μ m.

729 **G.** Ki67 and α SMA staining of organoids treated with FGF2-wt or FGF2-STAB for 3 or 5 days and
730 quantification of α SMA- / α SMA+ cell proportion among Ki67+ cells. Scale bars, 50 μ m. The plots show
731 mean + s.d., N = 11-50 organoids per condition (see [Supplemental Table 5](#)). ** P < 0.01, ****P < 0.0001
732 (two-way ANOVA).

733 **H.** Endoplasmic reticulum (EnR) thickness and mitochondrial area of organoids. The plots show mean
734 \pm s.d. N = 116, 234, and 436 of ER cisternae, and 17, 19, and 17 mitochondria from organoids treated
735 with no FGF, FGF2-wt, or FGF2-STAB for 5 days, respectively. ***P < 0.001; ****P < 0.0001 (one-way
736 ANOVA).

737 **I.** Primary, secondary and tertiary mammosphere formation efficiency (MFE) of cells from organoids
738 cultured with no FGF, FGF2-wt, or FGF2-STAB for 5 days. The plots show mean + s.d., n = 2 independent
739 experiments. *P < 0.05 (one-way ANOVA).




740

741 **Figure 3. FGF2 signaling dynamics regulates epithelial branching via ERK signaling.**

742 **A.** Organoids cultured with FGF2-wt or FGF2-STAB and with or without ERK inhibitor U0126 for 9 days.
743 Insets show organoids on day 0. Scale bars, 200 μ m.

744 **B.** Quantification of organoid morphogenetic response – total branching or massive growth – to ERK
745 inhibitor at a range of concentrations. The plots show mean + s.d., n = 2-4 independent experiments,
746 N = 20 organoids per experiment; for exact numbers see [Supplemental Table 4](#). *P < 0.05; **P < 0.01;
747 ***P < 0.001 (one-way ANOVA).

- 748 **C.** Histological and immunofluorescence analysis of FGF2-STAB-treated organoid architecture upon
749 ERK inhibitor treatment. H and E, hematoxylin and eosin; KRT5, keratin 5; KRT8, keratin 8. Scale bars,
750 100 μm .
- 751 **D.** Phosphorylated ERK (pERK) distribution in sections of organoids treated with 1 nM FGF2-wt or FGF2-
752 STAB. Scale bars, 200 μm .
- 753 **E.** Western blot analysis of pERK, total ERK, and β -actin amount in organoids on day 5 in culture, 48 h
754 after FGF2 treatment.
- 755 **F.** qPCR analysis of *Dusp6*, *Etv4* and *Etv5* gene expression in organoids on day 5 in culture, 48 h after
756 FGF2 treatment. The plots show mean + s.d., n = 2. *P < 0.05; **P < 0.01 (one-way ANOVA).
- 757 **G.** Distribution of pERK in basal (αSMA^+) and luminal (αSMA^-) cells in a section of organoid treated
758 with FGF2-STAB for 5 days. Scale bars, 50 μm .




759

760 **Figure 4. AKT signaling is crucial for sustained FGF2 signaling-induced epithelial stratification.**

761 **A.** Organoids cultured with FGF2-wt or FGF2-STAB and with or without AKT inhibitor (Akti) for 9 days
 762 of culture. The images of organoids without inhibitor are the same as in [Figure 3A](#) because they are
 763 from the same experiment. Insets show organoids on day 0. Scale bars, 200 μ m.

764 **B.** Quantification of organoid morphogenetic response – total branching or massive growth – to
 765 Akti1/2 at a range of concentrations. The plots show mean + s.d., n = 2-5 independent experiments,
 766 N = 20 organoids per experiment; for exact numbers see [Supplemental Table 4](#). *P < 0.05; **P < 0.01;
 767 ***P < 0.001 (one-way ANOVA).

- 768 **C.** Histological and immunofluorescence analysis of FGF2-STAB-treated organoid architecture upon
769 Akti treatment. H and E, hematoxylin and eosin; KRT5, keratin 5; KRT8, keratin 8. Scale bars, 100 μ m.
- 770 **D.** Western blot analysis of phosphorylated AKT (pAKT), total AKT and β -actin level in organoids on day
771 5 of culture, 48 h after treatment with FGF2.
- 772 **E.** Organoid morphogenesis in response to FGF2-STAB and no inhibitor or AKT inhibitor (0.5 μ M
773 Akti1/2) added on day 0, 3 or 6 of culture. The images are snapshots from time-lapse imaging of the
774 organoids. Scale bars, 200 μ m.
- 775 **F.** FGF2-STAB-treated organoid size upon no inhibitor or treatment with Akti1/2 on day 0, 3, or 6. The
776 plot shows mean + s.d., n = 1 experiment, N = 20 organoids per condition. **P < 0.01; ****P < 0.0001
777 (one-way ANOVA). Pink asterisks: control (no inhibitor) to inhibitor on day 6; red asterisks control to
778 inhibitor on day 3; dark red asterisks control to inhibitor on day 0).
- 779 **G.** Quantification of organoid total branching and massive growth in cultures from **D**. N = 20 organoids
780 per condition.



781

782

Figure 5. Massive branches phenocopy TEBs.

783 **A.** Organoid morphogenesis in response to FGF2-wt and FGF2-STAB in Matrigel (M) or a mixture of
 784 Matrigel with collagen (C). Scale bars, 100 μ m. Representative results of 3 independent biological
 785 replicates.

786 **B.** Quantification of branch elongation in a mixture of Matrigel with collagen as branch length to width
787 ratio. The plot shows mean + s.d., N = 71 (wt, M), 34 (wt, C), 48 (STAB, M) and 50 (STAB, C) branches.
788 **C.** Maximum intensity projection (MIP) and surface reconstruction images of organoids cultured in a
789 mixture of Matrigel with collagen (fluorescently labelled) and imaged using a confocal microscope.
790 Scale bars, 100 μ m.

791 **D.** Hematoxylin and eosin (H and E; top row), immunohistochemical (second and third row), and
792 immunofluorescence (bottom row) staining on sections of organoids with normal or massive branches,
793 and of side branches and TEB in mammary gland tissue. Scale bars, 100 μ m.

794 **E.** Scheme depicting morphology of myoepithelial cells (green) with height/width ratio lower or equal
795 to 1. Luminal cells are shown as grey.

796 **F.** Quantification of myoepithelial cell height to width ratio of mammary gland side branches and TEBs,
797 and normal branches of FGF2-wt-treated organoid and massive branches of FGF2-STAB-treated
798 organoids. The plot shows mean + s.d., N = 155 (duct), 98 (TEB), 128 (normal br.) and 423 (massive br.)
799 myoepithelial cells. ****P < 0.0001; (one-way ANOVA).

800 **G.** Schematics of cell behaviors and underlying signaling activities in the mammary gland and in ex vivo
801 mammary organoid cultures upon different FGF signaling dynamics. MG, mammary gland; TEB,
802 terminal end bud.